Beyonttra®▼(acoramidis)
About ATTR-CM
How does transthyretin amyloid cardiomyopathy (ATTR-CM) develop and progress?
- Transthyretin, or TTR for short, is an important transport protein in the body. ATTR-CM develops when transthyretin becomes unstable and breaks apart.
- In their natural state, TTR proteins stay tightly packed together in a group of four, called a tetramer. When TTR tetramers become unstable, they separate into four single units, called monomers. These monomers can change shape and begin to clump together as long fibres called amyloid fibrils. Over time, these fibrils can build into harmful deposits known as amyloid deposits. In ATTR-CM, these deposits accumulate in the heart, among other places, which can weaken the heart muscle and reduce its ability to pump blood effectively.
- ATTR-CM is a serious condition and, if left untreated, will progressively worsen over time.
Types of ATTR-CM:
- When the TTR protein breaks down because of a genetic mutation (it can be passed on to subsequent generations), it is called variant TTR amyloidosis (ATTRv).Different mutations can lead to different types of variant TTR amyloidosis. It tends to be more common in individuals of specific ethnic backgrounds, including people of African, Portuguese, Irish (Donegal variant), Swedish or Japanese descent.
- Conversely, if the TTR protein breaks apart without a genetic mutation, it is known as wild-type TTR amyloidosis (ATTRwt).The exact reason for TTR breakdown in this form is still being studied.
- If, with TTR amyloidosis, the amyloids predominantly collect in the nervous system, this is referred to as TTR amyloidosis with polyneuropathy; ATTR-PNfor short.
- Finally, in cases where amyloids predominantly collect in the heart muscle, this is referred to as transthyretin amyloid cardiomyopathy; ATTR-CMfor short.
Signs and Symptoms of ATTR-CM by Organ Class
Abbreviations:
ATTR-CM, transthyretin amyloid cardiomyopathy; TTR, transthyretin; ATTRv, variant TTR amyloidosis; ATTRwt, wild-type TTR amlyloidosis; ATTR-PN, TTR amyloidosis with polyneuropathy
PP-BEY-IE-0035-1 | November 2025
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.